IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
Go back to IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked| (NASDAQ: ICCM) | Delayed: 5.93 +0.53 (9.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.40 | 52 Week High | $ | |||
| Open | $7.06 | 52 Week Low | $ | |||
| Day High | $7.53 | P/E | N/A | |||
| Day Low | $5.61 | EPS | $ | |||
| Volume | 15,876,446 | |||||

